Tackling Solubility Challenges - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tackling Solubility Challenges
Nanosupensions are among the ways formulation scientists seek to address the problem of solubility.

Pharmaceutical Technology
Volume 36, Issue 3, pp. 40-44


1. R.O. Williams, A.B. Watts, and D.A. Miller, "Preface" in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), p. v–viii.

2. K.P. O'Donnell and R.O. Williams, "Optimizing the Formulation of Poorly Water- Soluble Drugs," in Formulating Poorly Water-Soluble Drugs, R.O. Williams, A.B. Watts, and D.A. Miller, Eds. (Springer, 2012), pp. 27–28.

3. FDA, Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification (Rockville, MD, Aug. 2000).

4. A.H. Jens-Uwe and R. H. Mueller, Int. J. Nanomedicine 3 (3), 295–310 (2008).

5. H. Chen et al., Drug. Discov. Today 16 (7–8), 354–360 (2011).

6. Alkermes, "NanoCrystal Technology" company information, http://www.alkermes.com/Contract-Services/Technologies/Bioavailability-Enhancement, accessed Feb. 13, 2012.

7. SkyePharma, "2011 Half-Year Results" (London, Aug. 18, 2011).

8. SkyePharma, "Insoluble Drug Delivery Platform" company information, http://www.skyepharma.com/Technology/Oral_Technology/Particle_Engineering_Technologies/Insoluble_Drug_Delivery_Platform/Default.aspx?id=80, accessed Feb. 13, 2012.

9. Aptalis Pharmaceutical Technologies, "Biorise Technology" company information, http://www.aptalispharmaceuticaltechnologies.com/tech_biorise.html, accessed Feb. 13, 2012.

10. B. Trout et al., J. Pharm. Sci. 101 (3), 1178–1188 (2012).

11. P. Van Arnum, Pharm. Technol. 32 (7), 96–98 (2007).

12. P. Van Arnum, Pharm. Technol. 35 (7), 46 (2011).

13. J.Q. Thomassen and P. Holm, presentation at the Nanomedicine and Drug Delivery Symposium (Toronto, Nov. 2008).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here